Changing landscape of antiviral resistance management in chronic hepatitis B

J Gastroenterol Hepatol. 2008 Sep;23(9):1314-7. doi: 10.1111/j.1440-1746.2008.05551.x.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Administration, Oral
  • Alanine Transaminase / blood
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • DNA, Viral / blood
  • Drug Resistance, Multiple, Viral* / genetics
  • Guanine / administration & dosage
  • Guanine / adverse effects
  • Guanine / analogs & derivatives*
  • Guanine / therapeutic use
  • Hepatitis B Antibodies / blood
  • Hepatitis B e Antigens / blood
  • Hepatitis B virus / drug effects
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology
  • Hepatitis B, Chronic / diagnosis
  • Hepatitis B, Chronic / drug therapy*
  • Hepatitis B, Chronic / pathology
  • Humans
  • Lamivudine / therapeutic use*
  • Polymerase Chain Reaction / methods
  • Predictive Value of Tests
  • Time Factors
  • Treatment Failure
  • Viral Load

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis B Antibodies
  • Hepatitis B e Antigens
  • Lamivudine
  • entecavir
  • Guanine
  • Alanine Transaminase